Expertise in
24
conditions

Dr. Lauren R. Weintraub

Hematology | Oncology
Albany Medical Center
43 New Scotland Ave, 
Albany, NY 
Expertise in
24
conditions
Albany Medical Center
43 New Scotland Ave, 
Albany, NY 

Overview

Lauren Weintraub is a Hematologist and an Oncologist practicing medicine in Albany, New York.

Dr. Weintraub is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Gliomatosis Cerebri, Glioma, Ependymoma, Medulloblastoma, and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 18 peer reviewed articles and participating in 48 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in NY

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MVP Health
  • EPO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Albany Medical Center
43 New Scotland Ave, Albany, NY 12208

Additional Areas of Focus

Dr. Weintraub has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

48 Clinical Trials

A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological
Study Drugs: Axitinib, Nivolumab
Study Phase: Phase 2
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study
Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study
Enrollment Status: Completed
Publish Date: August 28, 2026
Intervention Type: Other, Procedure
Study Phase: Not Applicable
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate
Study Phase: Phase 3
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, Filgrastim, Nivolumab, Pegfilgrastim, Prednisolone, Prednisone, Rituximab, Rituximab+Hyaluronidase Human, Vincristine Sulfate
Study Phase: Phase 3
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Procedure, Other, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors
StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2026
Intervention Type: Other, Behavioral, Device
Study Phase: Phase 3
View 9 Less Clinical Trials

18 Total Publications

Molecular and Clinical Stratification of Astroblastomas: Three distinct Fusion-Defined Groups Informing Risk-Adapted Treatment Strategies.
Molecular and Clinical Stratification of Astroblastomas: Three distinct Fusion-Defined Groups Informing Risk-Adapted Treatment Strategies.
Journal: Neuro-oncology
Published: June 02, 2025
Similar Doctors
Expertise in
46
conditions
Dr. Makenzi C. Evangelist
Hematology | Oncology
Expertise in
46
conditions
Dr. Makenzi C. Evangelist
Hematology | Oncology
Referral may be required

Albany Medical Center

43 New Scotland Ave, 
Albany, NY 
 (0.1 miles away)
518-262-6696
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Makenzi Evangelist is a Hematologist and an Oncologist practicing medicine in Albany, New York. Dr. Evangelist is highly rated in 46 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, and Non-Small Cell Lung Cancer (NSCLC).

Expertise in
28
conditions
Dr. Rahul Ravilla
Hematology | Oncology
Expertise in
28
conditions
Dr. Rahul Ravilla
Hematology | Oncology
Referral may be required

St. Peter's Health Partners Medical Associates P.C.

400 Patroon Creek Blvd, 
Albany, NY 
 (2.5 miles away)
518-262-6696
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rahul Ravilla is a Hematologist and an Oncologist practicing medicine in Albany, New York. Dr. Ravilla is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Upper Tract Urothelial Carcinoma (UTUC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, and Clear Cell Sarcoma.

Expertise in
26
conditions
Dr. Ira L. Zackon
Hematology | Oncology
Expertise in
26
conditions
Dr. Ira L. Zackon
Hematology | Oncology
Referral may be required

Albany Medical Center

43 New Scotland Ave, 
Albany, NY 
 (0.1 miles away)
518-262-6696
Languages Spoken:
English
See accepted insurances

Ira Zackon is a Hematologist and an Oncologist practicing medicine in Albany, New York. Dr. Zackon is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Plasmacytoma, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Lauren R. Weintraub

How do I make an appointment with Dr. Lauren R. Weintraub?

You can book an appointment with Dr. Lauren R. Weintraub by calling their office at 518-262-5513. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Lauren R. Weintraub a top-rated expert for Gliomatosis Cerebri?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lauren R. Weintraub is classified as an Distinguished expert for Gliomatosis Cerebri, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Lauren R. Weintraub specialize in?

While Dr. Lauren R. Weintraub is a Hematology, they have specific expertise in Gliomatosis Cerebri, Glioma, and Ependymoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Lauren R. Weintraub participate in research or clinical trials?

Yes. Dr. Lauren R. Weintraub has published 18 articles and abstracts on conditions like Gliomatosis Cerebri. You can view a list of Dr. Lauren R. Weintraub's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Lauren R. Weintraub accept my insurance?

Dr. Lauren R. Weintraub accepts most major insurance plans, including Anthem BCBS and Capital District Physicians Health. We recommend calling the office directly at 518-262-5513 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Weintraub's expertise for a condition
ConditionClose
    View All 19 Advanced Conditions
    View All 66 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile